<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204138.ref014">
 <label>14</label>
 <mixed-citation publication-type="book">
  <name>
   <surname>Mera</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>McCallister</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Palmer</surname>
   <given-names>B</given-names>
  </name>, 
  <name>
   <surname>Mayer</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Magnuson</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Rawlings</surname>
   <given-names>MK</given-names>
  </name>. 
  <chapter-title>FTC/TDF (Truvada) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2012–2015</chapter-title>
  <publisher-name>Gilead Sciences, Inc.,</publisher-name>
  <publisher-loc>Foster City, CA, USA</publisher-loc> International AIDS Conference in Durban, 17–22 July 2016. Oral abstract TUAX0105LB. Available at: 
  <ext-link ext-link-type="uri" xlink:href="http://programme.aids2016.org/" xmlns:xlink="http://www.w3.org/1999/xlink">http://programme.aids2016.org/</ext-link>. Last accessed on 2 July 2016.
 </mixed-citation>
</ref>
